<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>NGF (nerve growth factor) and BDNF (brain-derived neurotrophic factor) are protein molecules (MW 26 and 13.6 kDa, respectively) that are neuroprotective in the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) rat <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="1" pm="."><plain>Their mechanism of action involves the activation of transcription factor AP-1 that turns on neuronal growth genes </plain></SENT>
<SENT sid="2" pm="."><plain>In our ongoing studies we are designing short <z:chebi fb="7" ids="16670">peptides</z:chebi> that mimic some of the properties of full-length neurotrophic factors </plain></SENT>
<SENT sid="3" pm="."><plain>We have synthesized a neuroprotective 14-amino acid <z:chebi fb="7" ids="16670">peptide</z:chebi> (CMX-9236) with an N-terminal <z:chebi fb="0" ids="36005">docosahexaenoic acid</z:chebi> (DHA) </plain></SENT>
<SENT sid="4" pm="."><plain>DHA enhances entry through the blood-brain barrier </plain></SENT>
<SENT sid="5" pm="."><plain>Using primary rat brain cortical cultures and a fluorescent assay we found that CMX-9236 can counteract the excitotoxic effects of <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> or kainate, reversing the intracellular accumulation of Ca(2+) to <z:mpath ids='MPATH_458'>normal</z:mpath> levels </plain></SENT>
<SENT sid="6" pm="."><plain>Administration (i.v.) of CMX-9236 post initiation of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> reduced the lesion volumes from 178+/-50 to 117+/-55 mm(3) in the temporary rat MCAO model (90 min), and from 216+/-58 to 127+/-57 mm(3) in the permanent (24 h) model for <z:hpo ids='HP_0001297'>stroke</z:hpo>, corresponding to 34+/-28% (P=0.01) and 41+/-19% (P=0.038) reductions of the <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes </plain></SENT>
<SENT sid="7" pm="."><plain>Neurological behavior scores showed 57 and 47% improvements for treated temporary and permanent models, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Dose-response studies indicated a 60-fold activation of AP-1 transcription factor in cells treated with 100 ng/ml of the <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>These studies illustrate that a small <z:chebi fb="7" ids="16670">peptide</z:chebi> can function as a neuroprotective agent and an activator of a beneficial signal transduction pathway </plain></SENT>
</text></document>